Pyrosequencing™-Based Screening for Genetic Polymorphisms in Cytochrome P450 2B6 of Potential Clinical Relevance

• Nolan D , PhillipsE, MallalS: Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance.Clin. Infect. Dis.42 , 408–410 (2006).
   PubMed Web of Science ®Google Scholar
• Rotger M , ColomboS, FurrerH et al.: Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genomics15 , 1–5 (2005).
   PubMedGoogle Scholar
• Haas DW , RibaudoHJ, KimRB et al.: Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS18 , 2391–2400 (2004).
   PubMed Web of Science ®Google Scholar
• Ward BA , GorskiJC, JonesDR, HallSD, FlockhartDA, DestaZ: The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.J. Pharmacol. Exp. Ther.306 , 287–300 (2003).
   PubMed Web of Science ®Google Scholar
• Haas DW , SmeatonLM, ShaferRW et al.: Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult Aids Clinical Trials Group Study. J. Infect. Dis.192 , 1931–1942 (2005).
   PubMed Web of Science ®Google Scholar
• Tsuchiya K , GatanagaH, TachikawaN et al.: Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem. Biophys. Res. Commun.319 , 1322–1326 (2004).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S , BarreiroP, RendonA, Jimenez-NacherI, Gonzalez-LahozJ, SorianoV: Influence of 516G>T polymorphisms at the gene encoding the CYP450–2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects.Clin. Infect. Dis.40 , 1358–1361 (2005).
   PubMed Web of Science ®Google Scholar
• Ribaudo HJ , HaasDW, TierneyC et al.: Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin. Infect. Dis.42 , 401–407 (2006).
   PubMed Web of Science ®Google Scholar
• Hasse B , GunthardHF, BleiberG, Krause M: Efavirenz intoxication due to slow hepatic metabolism. Clin. Infect. Dis.40 , E22–E23 (2005).
   PubMed Web of Science ®Google Scholar
• Hoffman SM , NelsonDR, KeeneyDS: Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19.Pharmacogenetics11 , 687–98 (2001).
   PubMedGoogle Scholar
• Lang T , KleinK, FischerJ et al.: Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics11 , 399–415 (2001).
   PubMedGoogle Scholar
• Lamba V , LambaJ, YasudaK et al.: Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J. Pharmacol. Exp. Ther.307 , 906–22 (2003).
   PubMed Web of Science ®Google Scholar
• Lang T , KleinK, RichterT et al.: Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J. Pharmacol. Exp. Ther.311 , 34–43 (2004).
   PubMed Web of Science ®Google Scholar
• Hesse LM , HeP, KrishnaswamyS, HaoQ, HoganK, von Moltke LL et al.: Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics14 , 225–238 (2004).
   PubMedGoogle Scholar
• Zukunft J , LangT, RichterT et al.: A natural CYP2B6 TATA box polymorphism (-82T→ C) leading to enhanced transcription and relocation of the transcriptional start site. Mol. Pharmacol.67 , 1772–1782 (2005).
   PubMed Web of Science ®Google Scholar
• Klein K , LangT, SausseleT et al.: Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet. Genomics15 , 861–873 (2005).
   PubMed Web of Science ®Google Scholar
• Code EL , CrespiCL, PenmanBW, GonzalezFJ, ChangTK, WaxmanDJ: Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation.Drug Metab. Dispos.25 , 985–993 (1997).
   PubMed Web of Science ®Google Scholar
• Hesse LM , VenkatakrishnanK, CourtMH et al.: CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab. Dispos.28 , 1176–1183 (2000).
   PubMed Web of Science ®Google Scholar
• Faucette SR , HawkeRL, LecluyseEL et al.: Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab. Dispos.28 , 1222–1230 (2000).
   PubMed Web of Science ®Google Scholar
• Granvil CP , MadanA, SharkawiM, ParkinsonA, WainerIW: Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes.Drug Metab. Dispos.27 , 533–541 (1999).
   PubMed Web of Science ®Google Scholar
• Chang TK , WeberGF, CrespiCL, Waxman DJ: Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res53 , 5629–37 (1993).
   Google Scholar
• Erickson DA , MatherG, TragerWF, Levy RH, Keirns JJ: Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P450. Drug Metab. Dispos.27 , 1488–1495 (1999).
   PubMed Web of Science ®Google Scholar
• Bumpus NN , SridarC, KentUM, HollenbergPF: The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P4502B6 exhibits alterations in substrate metabolism and inactivation.Drug Metab. Dispos.33 , 795–802 (2005).
   PubMed Web of Science ®Google Scholar
• Ronaghi M , KaramohamedS, PetterssonB, UhlenM, NyrenP: Real-time DNA sequencing using detection of pyrophosphate release.Anal. Biochem.242 , 84–89 (1996).
   PubMed Web of Science ®Google Scholar
• Gaut BS , LongAD: The lowdown on linkage disequilibrium.Plant Cell15 , 1502–1506 (2003).
   PubMed Web of Science ®Google Scholar
• Jacob RM , JohnstoneEC, NevilleMJ, WaltonRT: Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping.Clin. Chem.50 , 1372–1377 (2004).
   PubMed Web of Science ®Google Scholar
• Alderborn A , KristoffersonA, Hammerling U: Determination of single-nucleotide polymorphisms by real-time pyrophosphate DNA sequencing. Genome Res.10 , 1249–1258 (2000).
   PubMed Web of Science ®Google Scholar
• Darimont J , GroschS, SkarkeC, Geisslinger G, Lotsch J: Comparison of two screening methods for in-house genotyping in clinical pharmacology units. Int. J. Clin. Pharmacol. Ther.43 , 17–22 (2005).
   PubMed Web of Science ®Google Scholar
• Xie HJ , YasarU, LundgrenS et al.: Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J.3 , 53–61 (2003).
   PubMed Web of Science ®Google Scholar
• Jinno H , Tanaka-KagawaT, OhnoA et al.: Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab. Dispos.31 , 398–403 (2003).
   PubMed Web of Science ®Google Scholar
• Ariyoshi N , MiyazakiM, ToideK, SawamuraY, KamatakiT: A single nucleotide polymorphism of CYP2B6 found in Japanese enhances catalytic activity by autoactivation.Biochem. Biophys. Res. Commun.281 , 1256–1260 (2001).
   PubMed Web of Science ®Google Scholar
• Burger D , van der Heiden I, la Porte C et al.: Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br. J. Clin. Pharmacol.61 , 148–154 (2006).
   PubMed Web of Science ®Google Scholar
• Wang J , SonnerborgA, RaneA et al.: Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet. Genomics16 , 191–198 (2006).
   PubMed Web of Science ®Google Scholar
• Saitoh A , SinghKK, PowellCA et al.: An MDR1 -3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS19 , 371–380 (2005).
   PubMed Web of Science ®Google Scholar
• Takada K , ArefayeneM, DestaZ et al.: Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum.50 , 2202–2210 (2004).
   PubMed Web of Science ®Google Scholar
• Lerman C , ShieldsPG, WileytoEP et al.: Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics12 , 627–634 (2002).
   PubMedGoogle Scholar
• Rodriguez-Novoa S , BarreiroP, Jimenez-NacherI, RendonA, SorianoV: Pharmacogenetics in HIV therapy.AIDS Rev7 , 103–112 (2005).
   PubMed Web of Science ®Google Scholar

Websites

• Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee: CYP2B6 allele nomenclature. www.cypalleles.ki.se/cyp2b6.htm [accessed August14, 2006]
   Google Scholar
• National Center for Biotechnology Information: Basic Local Alignment Search Tool (BLAST) www.ncbi.nlm.nih.gov/BLAST/ [accessed August29, 2006]
   Google Scholar
• Qiqing Huang, University of Texas, USA www.scienceboard.net/resources/prodreviews.asp?cat=22&product=478 [accessed on August29, 2006]
   Google Scholar